Shaheenah Dawood

Shaheenah Dawood: Phase 2 RAMP201 Trial Leading to FDA Accelerated Approval of Avumetinib and Defactinib

Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:

“Phase 2 RAMP201 (ENGOTov60/GTG-UK/GOG3052)trial leading to FDA accelerated approval avumetinib and defactinib now published.”

Title: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Authors: Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew Clamp, Emily Prendergast, Ana Oaknin, Kari Ring, Nicoletta Colombo, Robert W. Holloway, Manuel Rodrigues, Hye Sook Chon, Charlie Gourley, Alessandro D. Santin, Premal H. Thaker, Christine Gennigens, Gregg Newman, Erin Salinas, Hagop Youssoufian, Kathleen N. Moore, Stephanie Lustgarten, David M. O’Malley, Toon Van Gorp, Rachel N. Grisham

Read Full Article on Journal of Clinical Oncology.

Shaheenah Dawood

More posts featuring Shaheenah Dawood on OncoDaily.

Alessandro D. Santin Ana Oaknin Andrew Clamp Bradley J. Monk cancer Carol Aghajanian Charlie Gourley Christine Gennigens David M. O'Malley Els Van Nieuwenhuysen Emily Prendergast Erin Salinas Gregg Newman Hagop Youssoufian Hye Sook Chon Kari Ring Kathleen N. Moore Manuel Rodrigues Nicoletta Colombo OncoDaily Oncology Premal H. Thaker Rachel N. Grisham Robert W. Holloway Stephanie Lustgarten Susana N. Banerjee Toon Van Gorp Véronique D’Hondt